Identification_NN of_IN Novel_NP Immunodominant_NP CD4+_NP Th1-Type_NP T-Cell_NN Peptide_NP Epitopes_NP from_IN Herpes_NP Simplex_NP Virus_NP Glycoprotein_NP D_NP That_DT Confer_NP Protective_NP Immunity_NP The_DT molecular_JJ characterization_NN of_IN the_DT epitope_NN repertoire_NN on_IN herpes_NN simplex_JJ virus_NN (_( HSV_NP )_) antigens_NNS would_MD greatly_RB expand_VB our_PP$ knowledge_NN of_IN HSV_NP immunity_NN and_CC improve_VB immune_JJ interventions_NNS against_IN herpesvirus_NN infections_NNS ._SENT HSV_NP glycoprotein_NN D_NP (_( gD_NN )_) is_VBZ an_DT immunodominant_JJ viral_JJ coat_NN protein_NN and_CC is_VBZ considered_VBN an_DT excellent_JJ vaccine_NN candidate_NN antigen_NN ._SENT By_IN using_VBG the_DT TEPITOPE_NP prediction_NN algorithm_NN ,_, we_PP have_VBP identified_VBN and_CC characterized_VBN a_DT total_NN of_IN 12_CD regions_NNS within_IN the_DT HSV_NP type_NN 1_CD (_( HSV-1_NP )_) gD_NN bearing_VBG potential_JJ CD4+_NP T-cell_NN epitopes_NNS ,_, each_DT 27_CD to_TO 34_CD amino_NN acids_NNS in_IN length_NN ._SENT Immunogenicity_NN studies_NNS of_IN the_DT corresponding_JJ medium-sized_JJ peptides_NNS confirmed_VBD all_DT previously_RB known_VBN gD_NN epitopes_NNS and_CC additionally_RB revealed_VBD four_CD new_JJ immunodominant_JJ regions_NNS (_( gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN )_) ,_, each_DT containing_VBG naturally_RB processed_JJ epitopes_NNS ._SENT These_DT epitopes_NNS elicited_VBD potent_JJ T-cell_NN responses_NNS in_IN mice_NNS of_IN diverse_JJ major_JJ histocompatibility_NN complex_NN backgrounds_NNS ._SENT Each_DT of_IN the_DT four_CD new_JJ immunodominant_JJ peptide_NN epitopes_NNS generated_VBD strong_JJ CD4+_NP Th1_NP T_NN cells_NNS that_WDT were_VBD biologically_RB active_JJ against_IN HSV-1-infected_JJ bone_NN marrow-derived_VBD dendritic_JJ cells_NNS ._SENT Importantly_RB ,_, immunization_NN of_IN H-2d_JJ mice_NNS with_IN the_DT four_CD newly_RB identified_VBN CD4+_NP Th1_NP peptide_NN epitopes_NNS but_CC not_RB with_IN four_CD CD4+_NP Th2_NP peptide_NN epitopes_NNS induced_VBD a_DT robust_JJ protective_JJ immunity_NN against_IN lethal_JJ ocular_JJ HSV-1_JJ challenge_NN ._SENT These_DT peptide_NN epitopes_NNS may_MD prove_VB to_TO be_VB important_JJ components_NNS of_IN an_DT effective_JJ immunoprophylactic_JJ strategy_NN against_IN herpes_NN ._SENT Genital,dermal_NP ,_, and_CC ocular_JJ herpes_NN simplex_NN virus_NN (_( HSV_NP )_) infections_NNS cause_VBP prevalent_JJ ,_, lifelong_JJ recurrent_JJ infections_NNS ,_, with_IN a_DT spectrum_NN of_IN clinical_JJ manifestations_NNS ,_, including_VBG cold_JJ sores_NNS ,_, genital_JJ lesions_NNS ,_, corneal_JJ blindness_NN ,_, and_CC encephalitis_NN ._SENT Despite_IN the_DT availability_NN of_IN many_JJ interventional_JJ strategies_NNS ,_, there_EX has_VBZ been_VBN a_DT constant_JJ increase_NN of_IN HSV_NP prevalence_NN during_IN the_DT last_JJ 3_CD decades_NNS ._SENT Several_JJ challenges_NNS face_VBP the_DT development_NN of_IN an_DT effective_JJ herpes_NN vaccine_NN that_WDT could_MD help_VB control_VB this_DT epidemic_NN ,_, including_VBG the_DT uncertainty_NN about_IN the_DT exact_JJ immune_JJ correlates_NNS of_IN protection_NN ,_, the_DT identification_NN of_IN immunogenic_JJ epitopes_NNS ,_, and_CC the_DT development_NN of_IN an_DT effective_JJ and_CC safe_JJ immunization_NN strategy_NN ._SENT Despite_IN previous_JJ emphasis_NN on_IN antibody_NN (_( Ab_NP )_) and_CC CD8+_NP T-cell_NN responses_NNS ,_, there_EX is_VBZ growing_VBG evidence_NN to_TO support_VB a_DT pivotal_JJ role_NN for_IN the_DT T-helper_NN type_NN 1_CD (_( Th1_NP )_) subset_NN of_IN CD4+_NP T_NN cells_NNS in_IN antiherpesvirus_NN immunity_NN ._SENT CD4+_JJ T_NN cells_NNS are_VBP required_VBN for_IN the_DT protection_NN of_IN mice_NNS from_IN HSV_NP challenge_NN ._SENT In_IN humans_NNS ,_, CD4+_NP T_NN cells_NNS are_VBP stimulated_VBN in_IN vivo_RB following_VBG an_DT HSV_NP infection_NN and_CC the_DT integrated_JJ CD4_NP memory_NN response_NN to_TO HSV_NP type_NN 1_CD (_( HSV-1_NP )_) appears_VBZ to_TO occur_VB in_IN up_IN to_TO 0.2_CD %_NN of_IN circulating_VBG CD4+_NP T_NN cells_NNS ._SENT Severe_JJ herpetic_JJ infections_NNS are_VBP often_RB seen_VBN in_IN immunocompromised_JJ individuals_NNS with_IN impaired_JJ T-cell_NN immunity_NN ,_, such_JJ as_IN AIDS_NP and_CC transplant_NN patients_NNS ,_, where_WRB the_DT immune_JJ defect_NN is_VBZ predominantly_RB displayed_VBN in_IN CD4+_NP T_NN cells_NNS ._SENT While_IN it_PP is_VBZ believed_VBN that_IN CD4+_NP T-cell_NN responses_NNS are_VBP important_JJ for_IN protection_NN in_IN general_NN ,_, the_DT importance_NN of_IN Th1-_NP versus_CC Th2-type_NP immune_JJ responses_NNS for_IN protection_NN against_IN HSV-1_JJ infection_NN is_VBZ still_RB under_IN investigation_NN ._SENT These_DT findings_NNS ,_, along_RB with_IN the_DT important_JJ role_NN of_IN CD4+_NP cells_NNS in_IN supporting_VBG both_DT B-cell_NN and_CC CD8+_JJ T-cell_NN functions_NNS ,_, suggest_VBP that_IN a_DT successful_JJ immunotherapeutic_JJ or_CC immunoprophylactic_JJ strategy_NN against_IN HSV-1_NP should_MD include_VB immunodominant_JJ CD4+_NP Th-cell_NN epitopes_NNS ._SENT Several_JJ lines_NNS of_IN evidence_NN point_NN to_TO glycoprotein_NN D_NP (_( gD_NN )_) being_VBG a_DT major_JJ target_NN of_IN HSV-1_JJ immune_JJ clearance_NN mechanisms_NNS and_CC ,_, therefore_RB ,_, an_DT excellent_JJ candidate_NN antigen_NN (_( Ag_NP )_) :_: (_( i_NP )_) it_PP is_VBZ highly_RB conserved_VBN and_CC antigenically_RB cross-reactive_JJ with_IN HSV-1_NP and_CC HSV-2_NP ,_, (_( ii_NNS )_) it_PP is_VBZ among_IN the_DT main_JJ target_NN Ags_NNS for_IN CD4+_NP T_NN cells_NNS in_IN HSV-seropositive_JJ individuals_NNS ,_, (_( iii_NNS )_) it_PP appears_VBZ to_TO play_VB a_DT vital_JJ role_NN in_IN initiating_VBG the_DT infectious_JJ process_NN ,_, and_CC (_( iv_NN )_) importantly_RB ,_, a_DT recent_JJ large_JJ human_JJ genital_JJ HSV_NP clinical_JJ trial_NN shows_VBZ that_DT immunization_NN with_IN gD_JJ recombinant_JJ protein_NN mixed_VBN with_IN alum_NN and_CC 3-O-deacylated-monophosphoryl_JJ lipid_NN A_DT adjuvants_NNS induced_VBD significant_JJ protection_NN against_IN clinically_RB apparent_JJ genital_JJ herpes_NN in_IN women_NNS who_WP were_VBD seronegative_JJ for_IN both_DT HSV-1_NP and_CC HSV-2_NP ._SENT The_DT gD_NN epitopes_NNS and_CC the_DT immune_JJ mechanism_NN that_WDT provide_VBP protective_JJ immunity_NN are_VBP not_RB yet_RB fully_RB understood_VBN ._SENT Knowledge_NN of_IN immune_JJ responses_NNS to_TO gD_NNS and_CC of_IN their_PP$ correlation_NN with_IN protection_NN is_VBZ limited_VBN primarily_RB to_TO the_DT identification_NN of_IN B-cell_NN epitopes_NNS ,_, with_IN only_RB a_DT limited_JJ number_NN of_IN T-cell_NN epitopes_NN having_VBG been_VBN reported_VBN to_TO date_NN ._SENT We_PP hypothesized_VBD that_DT characterization_NN of_IN the_DT CD4+_NP T-cell_NN epitope_NN repertoire_NN of_IN gD_NNS could_MD be_VB vital_JJ in_IN the_DT case_NN of_IN HSV_NP infection_NN ._SENT After_IN infection_NN ,_, CD4+_NP T_NN cells_NNS directed_VBD to_TO the_DT immunodominant_JJ epitopes_NNS of_IN gD_NNS might_MD have_VB been_VBN inactivated_VBN and_CC T_NN cells_NNS specific_JJ for_IN subdominant_JJ epitopes_NNS might_MD have_VB escaped_VBN T-cell_NN tolerance_NN ._SENT The_DT present_JJ study_NN was_VBD aimed_VBN at_IN identifying_VBG the_DT CD4+_NP T-cell_NN epitopes_NNS of_IN HSV-1_JJ gD_NNS and_CC determining_VBG the_DT role_NN of_IN CD4+_NP Th1_NP versus_CC CD4+_NP Th2_NP T-cell_NN epitopes_NNS in_IN protection_NN against_IN an_DT ocular_JJ HSV-1_JJ challenge_NN ._SENT We_PP analyzed_VBD HSV-1_JJ gD_NN for_IN CD4+_NP T-cell_NN epitopes_NNS by_IN a_DT combined_JJ approach_NN of_IN computational_JJ identification_NN of_IN candidate_NN T-cell_NN epitopes_NNS followed_VBN by_IN in_IN vitro_NN and_CC in_IN vivo_JJ biologic_JJ validation_NN ._SENT Many_JJ of_IN the_DT predicted_VBN gD_NN sequences_NNS were_VBD established_VBN as_IN forming_VBG natural_JJ epitopes_NNS recognized_VBN by_IN HSV-1-primed_NP CD4+_NP T_NN cells_NNS ,_, and_CC their_PP$ in_IN vivo_JJ function_NN was_VBD confirmed_VBN as_IN inducing_VBG a_DT CD4-dependent_JJ protective_JJ immunity_NN against_IN HSV_NP challenge_NN ._SENT Among_IN 12_CD predicted_VBD gD_NN sequences_NNS ,_, we_PP found_VBD four_CD new_JJ immunodominant_JJ peptide_NN epitopes_NNS (_( gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN )_) containing_VBG naturally_RB processed_VBN epitopes_NNS that_WDT selectively_RB induced_VBD a_DT strong_JJ Th1_JJ subset_NN of_IN CD4+_NP T_NN cells_NNS in_IN mice_NNS ._SENT Four_CD other_JJ epitope_NN peptides_NNS (_( gD22-52_NP ,_, gD77-104_NP ,_, gD200-234_NN ,_, and_CC gD287-317_JJ )_) were_VBD found_VBN to_TO preferentially_RB induce_VB the_DT Th2_JJ subset_NN of_IN CD4+_NP T_NN cells_NNS ._SENT Interestingly_RB ,_, immunization_NN with_IN the_DT newly_RB identified_VBN immunodominant_JJ CD4+_NP Th1_NP peptide_NN epitopes_NNS ,_, but_CC not_RB CD4+_NP Th2_NP peptide_NN epitopes_NNS ,_, induced_VBD CD4-dependent_JJ protective_JJ immunity_NN against_IN lethal_JJ HSV-1_JJ challenge_NN ._SENT The_DT peptide_NN epitopes_NNS described_VBN in_IN this_DT report_NN could_MD form_VB part_NN of_IN an_DT immunotherapeutic_JJ or_CC an_DT immunoprophylactic_JJ strategy_NN for_IN treating_VBG herpes_NN ._SENT T-cell_NN epitope_NN prediction_NN ._SENT |_SYM The_DT gD_NN sequence_NN (_( HSV-1_JJ strain_NN 17_CD )_) was_VBD loaded_VBN into_IN the_DT new_JJ prediction_NN software_NN (_( TEPITOPE_NP )_) to_TO predict_VB promiscuous_JJ epitopes_NNS ._SENT The_DT TEPITOPE_NP algorithm_NN is_VBZ a_DT Windows_NP application_NN that_WDT is_VBZ based_VBN on_IN 25_CD quantitative_JJ matrix-based_JJ motifs_NNS that_WDT cover_VBP a_DT significant_JJ part_NN of_IN human_JJ HLA_NP class_NN II_NP peptide_NN binding_VBG specificity_NN ._SENT The_DT algorithm_NN permits_VBZ the_DT prediction_NN and_CC parallel_JJ display_NN of_IN ligands_NNS for_IN each_DT of_IN the_DT 25_CD HLA-DR_NP alleles_NNS ._SENT The_DT TEPITOPE_NP prediction_NN threshold_NN was_VBD set_VBN at_IN 5_CD %_NN ,_, and_CC 12_CD regions_NNS ,_, predicted_VBD to_TO bind_VB at_IN least_JJS 50_CD %_NN of_IN the_DT major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_NN II_CD molecules_NNS were_VBD picked_VBN ._SENT The_DT peptide_NN gD253-278_NN (_( LPPELSETPNATQPELAPEDPEDSAL_NP )_) from_IN the_DT region_NN gD257-287_JJ and_CC the_DT peptide_NN gB728-761_NN (_( NAAMFAGLGAFFEGMGDLGRAVGKVVMGIVGGVV_NP )_) ,_, which_WDT were_VBD not_RB picked_VBN by_IN the_DT TEPITOPE_NP program_NN as_IN containing_VBG potential_JJ T-cell_NN epitopes_NNS ,_, were_VBD synthesized_VBN and_CC were_VBD used_VBN as_IN negative_JJ controls_NNS ._SENT Synthesis_NN of_IN peptides_NNS ._SENT |_SYM A_DT total_NN of_IN 14_CD peptides_NNS (_( 12_CD gD_NNS TEPITOPE-selected_JJ peptides_NNS and_CC 2_CD control_NN peptides_NNS not_RB selected_VBN by_IN TEPITOPE_NP ,_, i.e._FW ,_, gD253-278_JJ and_CC gB728-761_JJ )_) ,_, each_DT consisting_VBG of_IN 27_CD to_TO 34_CD amino_NN acids_NNS ,_, were_VBD synthesized_VBN by_IN BioSource_NP International_NP (_( Hopkinton_NP ,_, Mass._NP )_) on_IN a_DT 9050_CD Pep_NP Synthesizer_NP Instrument_NP by_IN using_VBG solid-phase_NN peptide_NN synthesis_NN and_CC standard_JJ 9-fluorenylmethoxy_JJ carbonyl_NN technology_NN (_( PE_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT Peptides_NNS were_VBD cleaved_VBN from_IN the_DT resin_NN by_IN using_VBG trifluoroacetic_JJ acid-anisole-thioanisole-anisole-ethanedithiol_NN (EDT)-water_NN (_( 87.5:2.5:2.5:2.5:5_CD %_NN )_) followed_VBN by_IN ether_NN (_( methyl-t-butyl_NN ether_NN )_) extraction_NN and_CC lyophilization_NN ,_, as_RB previously_RB described_VBN ._SENT The_DT purity_NN of_IN peptides_NNS was_VBD between_IN 75_CD and_CC 96_CD %_NN ,_, as_RB determined_VBN by_IN reversed-phase_JJ high-performance_JJ liquid_JJ chromatography_NN (_( Vydac_NP C18_NP )_) and_CC mass_JJ spectroscopy_NN (_( Voyager_NP MALDI-TOF_NP System_NP )_) ._SENT Stock_NN solutions_NNS were_VBD made_VBN at_IN 1_CD mg/ml_NN in_IN water_NN ,_, except_IN for_IN peptide_NN gD146-179_NN ,_, which_WDT was_VBD solubilized_VBN in_IN 5_CD %_NN dimethyl_NN sulfoxide_NN ._SENT All_DT peptides_NNS were_VBD aliquoted_VBN and_CC were_VBD stored_VBN at_IN -20C_NN until_IN assayed_VBN ._SENT All_DT studies_NNS were_VBD conducted_VBN with_IN the_DT immunogen_NN emulsified_VBN in_IN Montanide-ISA-720_NP adjuvant_NN (_( M-ISA-720_NP )_) (_( Seppic_NP ,_, Fairfield_NP ,_, N.J._NP )_) at_IN a_DT 30:70_CD ratio_NN ,_, which_WDT was_VBD immediately_RB injected_VBN in_IN mice_NNS ._SENT HSV-1_NP ._SENT |_SYM The_DT McKrae_NP strain_NN of_IN HSV-1_NP was_VBD used_VBN in_IN this_DT study_NN ._SENT The_DT virus_NN was_VBD triple_JJ plaque_NN purified_VBD and_CC was_VBD prepared_VBN as_IN previously_RB described_VBN ._SENT UV-inactivated_NP HSV-1_NP was_VBD made_VBN by_IN exposing_VBG the_DT live_JJ virus_NN to_TO a_DT Philips_NP 30-W_JJ UV_NP bulb_NN for_IN 10_CD min_NN at_IN a_DT distance_NN of_IN 5_CD cm_NN ._SENT Heat-killed_JJ virus_NN was_VBD made_VBN by_IN heating_VBG virus_NN solution_NN at_IN 100C_NP for_IN 5_CD min_NN ._SENT HSV_NP inactivation_NN was_VBD confirmed_VBN by_IN the_DT inability_NN to_TO produce_VB plaques_NNS when_WRB tested_VBN on_IN Vero_NP cells_NNS ._SENT Mice_NNS and_CC immunization_NN ._SENT |_SYM Six-_NP to_TO 8-week-old_JJ C57BL/6_NP (_( H-2b_NP )_) ,_, BALB/c_NP (_( H-2d_NP )_) ,_, and_CC C3H/HeJ_NP (_( H-2k_NP )_) mice_NNS ,_, purchased_VBN from_IN the_DT Jackson_NP Laboratory_NP (_( Bar_NP Harbor_NP ,_, Maine_NP )_) ,_, were_VBD used_VBN in_IN all_DT experiments_NNS ._SENT Groups_NNS of_IN five_CD mice_NNS per_IN strain_NN were_VBD immunized_VBN subcutaneously_RB with_IN peptides_NNS in_IN M-ISA-720_JJ adjuvant_NN on_IN days_NNS 0_CD and_CC 21_CD ._SENT Peptide-specific_JJ T-cell_NN assay_NN ._SENT |_SYM Twelve_CD days_NNS after_IN the_DT second_JJ immunization_NN ,_, spleen_NN and_CC inguinal_JJ lymph_NN nodes_NNS were_VBD removed_VBN and_CC placed_VBN in_IN ice-cold_JJ serum-free_JJ HL-1_JJ medium_NN supplemented_VBN with_IN 15_CD mM_NP HEPES_NP ,_, 5_CD x_SYM 10-5_CD M_NP beta-mercaptoethanol_NN ,_, 2_CD mM_NP glutamine_NN ,_, 50_CD U_NN of_IN penicillin_NN ,_, and_CC 50_CD mug_NN of_IN streptomycin_NN (_( GIBCO-BRL_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) (_( CM_NP )_) ._SENT The_DT cells_NNS were_VBD cultured_VBN in_IN 96-well_NN plates_NNS at_IN 5_CD x_SYM 105_CD cells/well_NN in_IN CM_NP ,_, with_IN recall_NN or_CC control_NN peptide_NN at_IN a_DT 30-_CD ,_, 10-_CD ,_, 3-_CD ,_, 1-_CD ,_, or_CC 0.3-mug/ml_NN concentration_NN ,_, as_RB previously_RB described_VBN ._SENT The_DT cell_NN suspensions_NNS were_VBD incubated_VBN for_IN 72_CD h_NN at_IN 37C_JJ in_IN 5_CD %_NN CO2_NN ._SENT One_CD microcurie_NN of_IN [_SYM 3H]thymidine_JJ (_( Dupont_NP NEN_NP ,_, Boston_NP ,_, Mass._NP )_) was_VBD added_VBN to_TO each_DT well_NN during_IN the_DT last_JJ 16_CD h_NN of_IN culture_NN ._SENT The_DT incorporated_JJ radioactivity_NN was_VBD determined_VBN by_IN harvesting_VBG cells_NNS onto_IN glass_NN fiber_NN filters_NNS and_CC counting_VBG on_IN a_DT Matrix_NP 96_CD direct_JJ ionization_NN counter_NN (_( Packard_NP Instruments_NP ,_, Meriden_NP ,_, Conn._NP )_) ._SENT Results_NNS were_VBD expressed_VBN as_IN the_DT mean_JJ counts_NNS of_IN cell-associated_NP [_SYM 3H]thymidine_JJ per_IN minute_NN recovered_VBN from_IN wells_NNS containing_VBG Ag_NP minus_CC the_DT mean_JJ counts_NNS of_IN cell-associated_NP [_SYM 3H]thymidine_JJ per_IN minute_NN recovered_VBN from_IN wells_NNS without_IN Ag_NP (_( Deltacpm_NP )_) (_( average_JJ of_IN triplicate_NN )_) ._SENT The_DT stimulation_NN index_NN (_( SI_NP )_) was_VBD calculated_VBN as_IN the_DT mean_JJ counts_NNS of_IN cell-associated_NP [_SYM 3H]thymidine_JJ per_IN minute_NN recovered_VBN from_IN wells_NNS containing_VBG Ag_NP divided_VBN by_IN the_DT mean_JJ counts_NNS of_IN cell-associated_NP [_SYM 3H]thymidine_JJ per_IN minute_NN recovered_VBN from_IN wells_NNS without_IN Ag_NP (_( average_NN of_IN triplicate_NN )_) ._SENT For_IN all_DT experiments_NNS the_DT irrelevant_JJ control_NN peptide_NN gB141-165_NN and_CC the_DT T-cell_NN mitogen_NN concanavalin_NP A_NP (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) were_VBD used_VBN as_IN negative_JJ and_CC positive_JJ controls_NNS ,_, respectively_RB ._SENT Proliferation_NN results_NNS were_VBD confirmed_VBN by_IN repeating_VBG each_DT experiment_NN twice_RB ._SENT A_DT T-cell_NN proliferative_JJ response_NN was_VBD considered_VBN positive_JJ when_WRB Deltacpm_NP was_VBD >_SYM 1,000_CD and_CC when_WRB the_DT SI_NP was_VBD >_SYM 2_CD ,_, as_RB previously_RB reported_VBN ._SENT CD4_NP and_CC CD8_NP blocking_VBG of_IN T-cell_NN responses_NNS ._SENT |_SYM Mice_NN were_VBD immunized_VBN with_IN a_DT gD_JJ peptide_NN ,_, and_CC splenocytes_NNS were_VBD isolated_VBN and_CC stimulated_VBN as_IN described_VBN above_IN ._SENT Stimulated_VBN splenocytes_NNS were_VBD then_RB incubated_VBN with_IN the_DT immunizing_VBG or_CC control_NN peptide_NN with_IN or_CC without_IN the_DT anti-CD4_JJ monoclonal_NN Ab_NP (_( MAb_NP )_) GK1.5_NP (_( PharMingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ._SENT Identically_RB prepared_VBN cultures_NNS were_VBD incubated_VBN with_IN anti-CD8_JJ MAb_NP 53-6.7_CD (_( PharMingen_NN )_) or_CC with_IN an_DT isotype-matched_JJ control_NN Ab_NP ,_, all_DT at_IN 10_CD mug/ml_NN ._SENT It_PP has_VBZ been_VBN previously_RB shown_VBN that_IN these_DT antibodies_NNS show_VBP the_DT expected_VBN specificities_NNS and_CC function_NN as_IN expected_VBN ._SENT Cytokine_NN analysis_NN ._SENT |_SYM T_NN cells_NNS were_VBD stimulated_VBN with_IN either_DT immunizing_VBG peptides_NNS (_( 10_CD mug/ml_NN )_) ,_, the_DT irrelevant_JJ control_NN peptide_NN (_( 10_CD mug/ml_NN )_) ,_, UV-inactivated_NP HSV-1_NP (_( multiplicity_NN of_IN infection_NN [_SYM MOI_NP ]_SYM =_SYM 3_CD )_) ,_, or_CC with_IN concanavalin_NP A_NP (_( 0.5_CD mug/ml_NN )_) as_IN a_DT positive_JJ control_NN ._SENT Culture_NN media_NNS were_VBD harvested_VBN at_IN 48_CD h_NN (_( for_IN interleukin_NN 2_CD [_SYM IL-2_NP ]_SYM )_) or_CC 96_CD h_NN (_( for_IN IL-4_NN and_CC gamma_NN interferon_NN [_SYM IFN-gamma_NP ]_SYM )_) and_CC were_VBD analyzed_VBN by_IN specific_JJ sandwich_NN enzyme-linked_JJ immunosorbent_JJ assay_NN following_VBG the_DT manufacturer_NN 's_POS instructions_NNS (_( PharMingen_NP )_) ._SENT Flow_NN cytometry_NN analysis_NN ._SENT |_SYM gD_JJ peptide-stimulated_JJ T_NN cells_NNS were_VBD phenotyped_VBN by_IN double_RB staining_VBG with_IN anti-CD4_NN and_CC anti-CD8_NN MAbs_NNS and_CC fluorescence-activated_JJ cell_NN sorter_NN analysis_NN ._SENT After_IN 4_CD days_NNS of_IN stimulation_NN with_IN a_DT 10_CD muM_NN concentration_NN of_IN each_DT peptide_NN ,_, 106_CD cells_NNS were_VBD washed_VBN in_IN cold_JJ phosphate-buffered_JJ saline-2_NN %_NN bovine_JJ serum_NN albumin_NN buffer_NN and_CC were_VBD incubated_VBN with_IN phycoerythrin_NN anti-CD4_NN (_( PharMingen_NP )_) or_CC with_IN fluorescein_NN isothiocyanate_NN anti-CD8_NP (_( PharMingen_NP )_) MAbs_NP for_IN 20_CD to_TO 30_CD min_NN on_IN ice_NN ._SENT Propidium_NN iodide_NN was_VBD used_VBN to_TO exclude_VB dead_JJ cells_NNS ._SENT For_IN each_DT sample_NN ,_, 20,000_CD events_NNS were_VBD acquired_VBN on_IN a_DT FACSCalibur_NP and_CC were_VBD analyzed_VBN with_IN CellQuest_NP software_NN on_IN an_DT integrated-power_NN Macintosh_NP G4_NP (_( Becton_NP Dickinson_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) ._SENT Bone_NN marrow-derived_JJ DC_NP ._SENT |_SYM Murine_NP bone_NN marrow-derived_VBD dendritic_JJ cells_NNS (_( DC_NP )_) were_VBD generated_VBN by_IN using_VBG a_DT modified_JJ version_NN of_IN the_DT protocol_NN that_WDT was_VBD described_VBN previously_RB ._SENT Briefly_RB ,_, bone_NN marrow_NN cells_NNS were_VBD flushed_VBN from_IN tibias_NNS and_CC femurs_NNS with_IN RPMI_NP 1640_CD ,_, and_CC a_DT single-cell_NN suspension_NN was_VBD made_VBN ._SENT A_DT total_NN of_IN 2_CD x_NN 106_CD cells_NNS were_VBD cultured_VBN in_IN 100-mm_NP tissue_NN dishes_NNS containing_VBG 10_CD ml_NN of_IN RPMI_NP 1640_CD supplemented_VBD with_IN 2_CD mM_NP glutamine_NN ,_, 1_CD %_NN nonessential_JJ amino_NN acids_NNS (_( GIBCO-BRL_NP )_) ,_, 10_CD %_NN fetal_JJ calf_NN serum_NN ,_, 50_CD ng_NNS of_IN granulocyte-macrophage_NN colony-stimulating_NN factor_NN per_IN ml_NN ,_, and_CC 50_CD ng_NNS of_IN IL-4_NN (_( PeproTech_NP Inc._NP )_) per_IN ml_NN ._SENT Cells_NNS were_VBD fed_VBN with_IN fresh_JJ media_NNS supplemented_VBN with_IN 25_CD ng_NNS of_IN granulocyte-macrophage_NN colony-stimulating_NN factor_NN per_IN ml_NN and_CC 25_CD ng_NNS of_IN IL-4_NN per_IN ml_NN every_DT 72_CD h._NN After_IN 7_CD days_NNS of_IN incubation_NN this_DT protocol_NN yielded_VBD 50_CD x_NN 106_CD to_TO 60_CD x_NN 106_CD cells_NNS ,_, with_IN 70_CD to_TO 90_CD %_NN of_IN the_DT nonadherent_JJ cells_NNS having_VBG typical_JJ DC_NP morphology_NN ._SENT This_DT was_VBD routinely_RB confirmed_VBN by_IN fluorescence-activated_JJ cell_NN sorter_NN analysis_NN of_IN CD11c_NP ,_, class_NN II_NP ,_, and_CC DEC-205_NP surface_NN markers_NNS of_IN DC_NP ._SENT CD4+-T-cell_NN responses_NNS to_TO HSV-infected_NP DC_NP ._SENT |_SYM CD4+_NP T-cell_NN lines_NNS specific_JJ to_TO each_DT of_IN the_DT gD_NN peptides_NNS were_VBD derived_VBN from_IN spleens_NNS of_IN immunized_VBN mice_NNS in_IN vitro_NN ,_, as_RB previously_RB described_VBN ._SENT To_TO test_VB the_DT biological_JJ relevance_NN of_IN these_DT peptide_NN epitopes_NNS ,_, CD4+_NP T-cell_NN effector_NN cells_NNS were_VBD incubated_VBN with_IN irradiated_JJ DC_NP (_( T-cell-to-DC_NP ratio_NN =_SYM 50:1_LS )_) infected_VBN with_IN UV-inactivated_NP HSV-1_NP (_( MOI_NP of_IN 3_CD ,_, 1_CD ,_, 0.3_CD ,_, or_CC 0.1_CD )_) and_CC lipopolysaccharide_NN (_( 1_CD mg/ml_NN )_) matured_VBN for_IN 24_CD h._NN As_IN a_DT control_NN CD4+_NP T_NN cells_NNS were_VBD also_RB incubated_VBN with_IN mock-infected_JJ DC_NP ._SENT DC_NP and_CC CD4+_NP T_NN cells_NNS were_VBD incubated_VBN for_IN 5_CD days_NNS at_IN 37C_JJ ._SENT [_SYM 3H]thymidine_JJ was_VBD added_VBN to_TO the_DT cultures_NNS 18_CD h_NN before_IN harvesting_NN ._SENT Proliferative_JJ responses_NNS were_VBD tested_VBN in_IN quadruplicate_JJ wells_NNS ,_, and_CC the_DT results_NNS were_VBD expressed_VBN as_IN mean_JJ counts_NNS per_IN minute_JJ +-_NN standard_NN deviation_NN ._SENT In_IN some_DT experiments_NNS ,_, splenocytes_NNS from_IN immunized_VBN or_CC control_NN mice_NNS were_VBD restimulated_VBN in_IN vitro_NN by_IN incubation_NN with_IN heat-inactivated_JJ or_CC UV-inactivated_JJ HSV-1_NP ._SENT In_IN vivo_JJ depletion_NN of_IN CD4+_NP and_CC CD8+_NP T_NN cells_NNS and_CC HSV-1_JJ challenge_NN ._SENT |_SYM Twenty_NP days_NNS after_IN the_DT second_JJ dose_NN of_IN peptide_NN immunogens_NNS ,_, mice_NNS were_VBD infected_VBN with_IN 2_CD x_SYM 105_CD PFU_NN per_IN eye_NN of_IN HSV-1_NP in_IN tissue_NN culture_NN media_NNS administered_VBN as_IN eyedrops_NNS in_IN a_DT volume_NN of_IN 10_CD mul_NN ._SENT In_IN some_DT experiments_NNS ,_, immunized_VBD mice_NNS were_VBD intraperitoneally_RB injected_VBN with_IN six_CD doses_NNS of_IN 0.1_CD ml_NN of_IN clarified_VBN ascetic_JJ fluid_NN in_IN 0.5_CD ml_NN of_IN phosphate-buffered_JJ saline_NN containing_VBG MAb_NP GK1.5_NP (_( anti-CD4_NP )_) or_CC MAb_NP 2.43_CD (_( anti-CD8_NN )_) on_IN days_NNS -7_CD ,_, -1_CD ,_, 0_CD ,_, 2_CD ,_, and_CC 5_CD postinfection_NN ._SENT Flow_NN cytometry_NN analysis_NN of_IN spleen_NN cells_NNS consistently_RB revealed_VBD a_DT decrease_NN in_IN CD4+_NP and_CC CD8+_NP T_NN cells_NNS in_IN treated_VBN mice_NNS to_TO levels_NNS of_IN <3_JJ %_NN of_IN those_DT of_IN normal_JJ mice_NNS ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Figures_NNS represent_VBP data_NNS from_IN two_CD or_CC three_CD independent_JJ experiments_NNS ._SENT The_DT data_NNS are_VBP expressed_VBN as_IN the_DT mean_JJ +-_NN standard_JJ error_NN of_IN the_DT mean_NN and_CC were_VBD compared_VBN by_IN using_VBG Student_NP 's_POS t_NN test_NN on_IN a_DT STATVIEW_NP II_NP statistical_JJ program_NN (_( Abacus_NP Concepts_NP ,_, Berkeley_NP ,_, Calif._NP )_) ._SENT Prediction_NN of_IN potential_JJ HSV-1_JJ gD_NN T-cell_NN epitopes_NNS by_IN the_DT TEPITOPE_NP algorithm_NN ._SENT |_SYM The_DT deduced_VBN primary_JJ amino_NN acid_NN sequence_NN of_IN the_DT HSV-1_JJ glycoprotein_NN gD_NNS was_VBD analyzed_VBN by_IN the_DT newly_RB developed_VBN T-cell_NN epitope_NN prediction_NN TEPITOPE_NP algorithm_NN ._SENT Twelve_CD regions_NNS bearing_VBG putative_JJ antigenic_JJ and_CC immunogenic_JJ determinants_NNS were_VBD detected_VBN by_IN using_VBG a_DT stringent_JJ threshold_NN ._SENT These_DT regions_NNS are_VBP probably_RB less_RBR constrained_VBN than_IN other_JJ parts_NNS of_IN the_DT molecule_NN and_CC therefore_RB more_RBR readily_RB accessible_JJ to_TO proteolysis_NN ,_, an_DT event_NN that_WDT precedes_VBZ T-cell_NN epitope_NN presentation_NN in_IN association_NN with_IN MHC_NP molecules_NNS ._SENT Medium-sized_JJ peptides_NNS corresponding_JJ to_TO the_DT 12_CD identified_VBN regions_NNS were_VBD synthesized_VBN ._SENT Ten_CD of_IN them_PP belong_VBP to_TO the_DT external_JJ N-terminal_JJ portion_NN of_IN gD_NN (_( gD1-29_JJ ,_, gD22-52_JJ ,_, gD49-82_JJ ,_, gD77-104_JJ ,_, gD96-123_JJ ,_, gD121-152_JJ ,_, gD146-179_JJ ,_, gD176-206_JJ ,_, gD200-234_JJ ,_, and_CC gD228-257_JJ )_) ._SENT One_PP lies_VBZ adjacent_JJ to_TO the_DT hydrophobic_JJ membrane_NN anchor_NN domain_NN of_IN gD_NN (_( gD287-317_JJ )_) ,_, and_CC one_PP is_VBZ part_NN of_IN the_DT proposed_VBN hydrophilic_JJ C-terminal_JJ cytoplasmic_JJ portion_NN of_IN gD_NN (_( gD332-358_NN )_) ._SENT It_PP should_MD be_VB noted_VBN that_IN ,_, of_IN the_DT 12_CD predicted_VBN regions_NNS ,_, six_CD mapped_VBN to_TO nonglycosylated_JJ regions_NNS of_IN gD_NN (_( gD1-29_JJ ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, gD287-317_JJ ,_, and_CC gD332-358_NN )_) ._SENT Peptides_NNS containing_VBG predicted_VBN gD_NN epitopes_NNS elicited_VBD potent_JJ CD4+_NP T_NN cells_NNS in_IN mice_NNS with_IN diverse_JJ MHC_NP backgrounds_NNS ._SENT |_SYM T-cell_NN immunogenicity_NN studies_NNS of_IN the_DT selected_VBN gD_NN peptides_NNS emulsified_VBN in_IN the_DT M-ISA-720_NP adjuvant_NN were_VBD carried_VBN out_RP in_IN H-2b_NP ,_, H-2d_NP ,_, and_CC H-2k_NP mice_NNS ._SENT In_IN an_DT initial_JJ experiment_NN ,_, we_PP investigated_VBD the_DT optimal_JJ dose_NN response_NN to_TO peptide_NN gD1-29_NN and_CC found_VBD no_DT differences_NNS between_IN doses_NNS of_IN 50_CD ,_, 100_CD ,_, and_CC 200_CD mug_NN ._SENT Subsequent_JJ experiments_NNS used_VBD 100_CD mug_NN (_( at_IN day_NN 0_CD )_) and_CC 50_CD mug_NN (_( at_IN day_NN 21_CD )_) of_IN each_DT peptide_NN ._SENT Peptide-specific_JJ T-cell_NN responses_NNS were_VBD determined_VBN from_IN both_CC the_DT spleen_NN and_CC the_DT lymph_NN node_NN cells_NNS ._SENT Depending_VBG on_IN the_DT peptides_NNS and_CC strain_NN of_IN mice_NNS used_VBN ,_, significant_JJ T-cell_NN proliferative_JJ responses_NNS were_VBD generated_VBN by_IN every_DT gD_JJ peptide_NN ._SENT Thus_RB ,_, each_DT of_IN the_DT 12_CD chosen_JJ regions_NNS contained_VBN at_IN least_JJS one_CD T-cell_NN epitope_NN ._SENT The_DT strongest_JJS T-cell_NN responses_NNS were_VBD directed_VBN primarily_RB ,_, although_IN not_RB exclusively_RB ,_, against_IN five_CD peptides_NNS (_( gD1-29_JJ ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN )_) ._SENT The_DT T-cell_NN responses_NNS of_IN H-2b_NP ,_, H-2d_NP ,_, and_CC H-2k_NP mice_NNS were_VBD focused_VBN on_IN the_DT same_JJ three_CD peptides_NNS (_( gD49-82_NP ,_, gD146-179_NN ,_, and_CC gD332-358_NN )_) ,_, suggesting_VBG that_IN they_PP contain_VBP dominant_JJ T-cell_NN epitopes_NNS ._SENT In_IN contrast_NN ,_, gD200-234_NN and_CC gD228-257_JJ appeared_VBD to_TO be_VB genetically_RB restricted_VBN to_TO H-2d_JJ mice_NNS ._SENT The_DT levels_NNS of_IN T-cell_NN response_NN were_VBD relatively_RB high_JJ with_IN a_DT Deltacpm_NP of_IN >=10,000_NN for_IN most_JJS peptides_NNS and_CC up_RB to_TO 50,000_CD cpm_NN for_IN gD332-358_NN ._SENT Although_IN relatively_RB moderate_JJ compared_VBN to_TO those_DT for_IN the_DT remaining_VBG gD_NN peptides_NNS ,_, the_DT responses_NNS to_TO gD22-52_NN ,_, gD77-104_NN ,_, and_CC gD96-123_NN were_VBD also_RB significant_JJ ._SENT A_DT peptide_NN derived_VBN from_IN the_DT region_NN gD257-287_NN (_( peptide_NN gD253-278_NN )_) ,_, which_WDT was_VBD not_RB picked_VBN by_IN the_DT TEPITOPE_NP program_NN as_IN containing_VBG a_DT potential_JJ T-cell_NN epitope_NN ,_, did_VBD not_RB induce_VB any_DT T-cell_NN response_NN in_IN any_DT of_IN the_DT strains_NNS of_IN mice_NNS used_VBN ._SENT The_DT specificity_NN of_IN the_DT proliferative_JJ responses_NNS was_VBD ascertained_VBN by_IN the_DT lack_NN of_IN response_NN after_IN restimulation_NN of_IN T_NN cells_NNS with_IN an_DT irrelevant_JJ peptide_NN (_( gB141-165_NN )_) and_CC the_DT lack_NN of_IN response_NN in_IN adjuvant-injected_JJ control_NN mice_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT CD4_JJ T_NN cells_NNS and_CC not_RB CD8_NP T_NN cells_NNS were_VBD important_JJ ._SENT |_SYM These_DT responses_NNS were_VBD abolished_VBN by_IN a_DT MAb_NP against_IN CD4_NP molecules_NNS but_CC not_RB by_IN a_DT MAb_NP against_IN CD8_NP ._SENT Collectively_RB ,_, these_DT results_NNS indicate_VBP that_IN gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN peptides_NNS are_VBP highly_RB immunogenic_JJ and_CC contain_VB at_IN least_JJS one_CD immunodominant_JJ CD4+_NP T-cell_NN epitope_NN ._SENT Priming_VBG of_IN multiple_JJ and_CC elevated_JJ T-cell_NN responses_NNS by_IN pools_NNS of_IN gD-derived_JJ peptides_NNS ._SENT |_SYM The_DT ability_NN of_IN pools_NNS of_IN gD_JJ peptides_NNS to_TO simultaneously_RB induce_VB multiple_JJ T_NN cells_NNS specific_JJ to_TO each_DT peptide_NN within_IN the_DT pool_NN was_VBD explored_VBN ._SENT In_IN these_DT experiments_NNS ,_, the_DT immunogenicity_NN in_IN H-2d_JJ mice_NNS of_IN pooled_JJ versus_CC individual_JJ peptides_NNS was_VBD compared_VBN side_NN by_IN side_NN to_TO investigate_VB if_IN there_EX was_VBD any_DT agonistic_JJ or_CC synergistic_JJ interaction_NN between_IN the_DT peptide_NN epitopes_NNS composing_VBG the_DT pool_NN ._SENT As_IN a_DT control_NN ,_, H-2d_JJ mice_NNS were_VBD injected_VBN with_IN M-ISA-720_NP alone_RB ._SENT Immunization_NN with_IN a_DT pool_NN of_IN gD1-29_NN ,_, gD49-82_NN ,_, and_CC gD332-358_NN peptides_NNS generated_VBD multiepitopic_JJ and_CC significantly_RB more_RBR elevated_JJ T-cell_NN responses_NNS specific_JJ to_TO each_DT peptide_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT Thus_RB ,_, when_WRB evaluated_VBN individually_RB ,_, each_DT peptide_NN induced_VBD a_DT relatively_RB lower_JJR response_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT In_IN a_DT similar_JJ experiment_NN ,_, the_DT responses_NNS induced_VBN by_IN a_DT pool_NN of_IN gD96-123_NN ,_, gD146-179_NN ,_, and_CC gD287-317_JJ peptides_NNS were_VBD also_RB at_IN higher_JJR than_IN the_DT responses_NNS induced_VBD when_WRB individual_JJ peptides_NNS were_VBD employed_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Several_JJ selected_JJ gD_NN epitope_NN peptides_NNS were_VBD identified_VBN as_IN targets_NNS of_IN IFN-gamma-_NP and_CC IL-2-secreting_NP CD4+_NP T_NN cells_NNS ._SENT |_SYM To_TO determine_VB the_DT subset_NN of_IN CD4+_NP T_NN cells_NNS induced_VBN by_IN each_DT gD_JJ peptide_NN ,_, we_PP studied_VBD the_DT pattern_NN of_IN peptide-specific_JJ IL-2_NP ,_, IL-4_NN ,_, and_CC IFN-gamma_NP cytokines_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, five_CD profiles_NNS of_IN cytokines_NNS were_VBD found_VBN :_: (_( i_NP )_) peptides_NNS gD1-29_JJ ,_, gD49-82_JJ ,_, gD96-123_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN induced_VBD strong_JJ Th1_JJ cytokine_NN (_( IFN-gamma_NP and_CC IL-2_NP )_) secretion_NN more_RBR efficiently_RB than_IN did_VBD the_DT remaining_VBG peptides_NNS ;_: (_( ii_NP )_) the_DT gD287-317_JJ peptide_NN induced_VBD low_JJ levels_NNS of_IN Th1_JJ cytokine_NN secretion_NN ;_: (_( iii_NP )_) the_DT gD22-52_NN and_CC gD77-104_NN peptides_NNS preferentially_RB induced_VBD Th-2_JJ cytokine_NN (_( IL-4_NN )_) ;_: (_( iv_NN )_) the_DT gD200-234_JJ peptide_NN induced_VBD a_DT mixed_JJ IFN-gamma-IL-4_NP response_NN ,_, since_IN both_DT cytokines_NNS were_VBD induced_VBN to_TO a_DT comparable_JJ extent_NN ;_: and_CC (_( v_NN )_) finally_RB ,_, the_DT gD121-152_NN and_CC gD176-206_NN peptides_NNS did_VBD not_RB induce_VB production_NN of_IN IL-2_NP ,_, IL-4_NN ,_, or_CC IFN-gamma_NP cytokines_NNS ._SENT Overall_RB ,_, most_JJS peptides_NNS induced_VBD IFN-gamma_NP and_CC IL-2_NP production_NN ,_, indicating_VBG that_IN the_DT selected_JJ HSV-1_JJ gD_NN peptides_NNS emulsified_VBN in_IN the_DT M-ISA-720_NP adjuvant_NN preferentially_RB elicited_VBD a_DT polarized_VBN Th1_JJ immune_JJ response_NN ._SENT Antibody_NN blocking_VBG of_IN T-cell_NN activity_NN revealed_VBD that_IN these_DT cytokines_NNS were_VBD mainly_RB produced_VBN by_IN CD4+_NP T_NN cells_NNS and_CC only_RB slightly_RB by_IN CD8+_NP T_NN cells_NNS ._SENT T_NN cells_NNS induced_VBN by_IN gD-peptides_NNS react_VBP to_TO the_DT native_JJ viral_JJ protein_NN ._SENT |_SYM Experiments_NP were_VBD performed_VBN to_TO determine_VB if_IN CD4+_NP T_NN cells_NNS induced_VBN by_IN gD_JJ synthetic_JJ peptides_NNS were_VBD reactive_JJ to_TO naturally_RB processed_VBN epitopes_NNS ,_, as_RB presented_VBN by_IN HSV-1-infected_JJ cells_NNS ._SENT CD4+_JJ T-cell_NN lines_NNS specific_JJ to_TO gD1-29_NN ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_JJ immunodominant_JJ Th1_JJ epitopes_NNS and_CC to_TO the_DT gD77-104_JJ subdominant_JJ epitope_NN were_VBD established_VBN from_IN H-2d_JJ mice_NNS ._SENT Recognition_NN of_IN autologous_JJ bone_NN marrow-derived_VBN DC_NP infected_VBN with_IN UV-inactivated_NP HSV-1_NP by_IN each_DT of_IN these_DT T-cell_NN lines_NNS was_VBD then_RB monitored_VBN in_IN a_DT proliferation_NN assay_NN ._SENT T-cell_NN lines_NNS specific_JJ to_TO gD1-29_NN ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN recognized_VBN UV-inactivated_NP HSV-infected_NP DC_NP ._SENT No_DT response_NN was_VBD observed_VBN when_WRB autologous_JJ mock-infected_JJ DC_NP were_VBD employed_VBN as_IN Ag-presenting_JJ cells_NNS ._SENT The_DT CD4+_NP T-cell_NN line_NN induced_VBN by_IN subdominant_JJ gD77-104_NN peptide_NN also_RB failed_VBD to_TO recognize_VB HSV-infected_NP DC_NP ._SENT Overall_RB ,_, these_DT results_NNS indicated_VBD that_IN processing_NN and_CC presentation_NN of_IN the_DT epitopes_NNS contained_VBN in_IN the_DT gD1-29_NN ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_JJ peptide_NN sequences_NNS occurred_VBD in_IN HSV-infected_JJ cells_NNS ._SENT In_IN subsequent_JJ experiments_NNS ,_, T-cell_NN proliferation_NN and_CC IFN-gamma_NP production_NN by_IN immune_JJ T_NN cells_NNS from_IN gD_JJ peptide-immunized_JJ mice_NNS were_VBD monitored_VBN against_IN whole_JJ HSV_NP as_IN Ag_NP by_IN using_VBG immune_JJ spleen_NN cells_NNS as_IN the_DT source_NN of_IN responding_VBG T_NN cells_NNS and_CC Ag-presenting_JJ cells_NNS ._SENT T_NN cells_NNS from_IN H-2b_NP ,_, H-2d_NP ,_, and_CC H-2k_NP mice_NNS immunized_VBN with_IN gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN exhibited_VBD significant_JJ proliferation_NN and_CC IFN-gamma_NP production_NN upon_IN in_IN vitro_NN stimulation_NN with_IN heat-killed_JJ HSV-1_NP ._SENT Under_IN the_DT same_JJ conditions_NNS ,_, T_NN cells_NNS from_IN the_DT adjuvant-injected_JJ control_NN mice_NNS did_VBD not_RB respond_VB to_TO heat-inactivated_JJ HSV-1-stimulation_NN ._SENT Thus_RB ,_, these_DT responses_NNS were_VBD Ag_NP specific_NN and_CC were_VBD not_RB due_JJ to_TO a_DT mitogenic_JJ effect_NN of_IN viral_JJ particles_NNS ._SENT These_DT HSV-1-specific_JJ T-cell_NN responses_NNS were_VBD strongly_RB reduced_VBN by_IN anti-CD4_NP MAb_NP treatment_NN but_CC not_RB by_IN anti-CD8_NP MAbs_NP ._SENT Lack_NN of_IN immunodominance_NN in_IN HSV-primed_JJ T-cell_NN responses_NNS to_TO selected_JJ gD-peptides_NNS ._SENT |_SYM To_TO determine_VB the_DT fine_JJ specificity_NN of_IN broadly_RB reactive_JJ T_NN cells_NNS associated_VBN with_IN viral_JJ immunity_NN and_CC to_TO explore_VB immunodominance_NN in_IN the_DT context_NN of_IN HSV_NP infection_NN ,_, proliferation_NN of_IN primed_VBN T_NN cells_NNS obtained_VBN from_IN 20_CD HSV-1-infected_JJ H-2d_NN mice_NNS were_VBD evaluated_VBN against_IN gD_NNS by_IN using_VBG each_DT of_IN the_DT 12_CD peptides_NNS as_IN Ag_NP ._SENT Although_IN the_DT selected_JJ peptides_NNS stimulated_VBN moderate_JJ gD-specific_JJ T-cell_NN responses_NNS ,_, surprisingly_RB ,_, the_DT in_IN vivo_JJ HSV-primed_JJ T_NN cells_NNS were_VBD reactive_JJ in_IN vitro_NN to_TO up_RB to_TO 10_CD of_IN the_DT 12_CD gD_JJ peptides_NNS (_( depending_VBG on_IN the_DT individual_JJ mouse_NN )_) ._SENT Despite_IN a_DT difference_NN between_IN individual_JJ mice_NNS ,_, a_DT broad_JJ range_NN of_IN gD-specific_JJ T_NN cells_NNS were_VBD primed_VBN in_IN all_DT of_IN the_DT 20_CD infected_JJ mice_NNS and_CC a_DT unique_JJ array_NN of_IN T-cell_NN responses_NNS was_VBD identified_VBN from_IN each_DT of_IN the_DT 20_CD infected_JJ mice_NNS analyzed_VBD ._SENT Seven_CD peptides_NNS (_( gD1-29_JJ ,_, gD49-82_JJ ,_, gD96-123_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, gD287-317_JJ ,_, and_CC gD332-358_NN )_) induced_VBD a_DT response_NN in_IN more_JJR than_IN 85_CD %_NN of_IN the_DT HSV-infected_JJ mice_NNS ._SENT The_DT responses_NNS were_VBD found_VBN to_TO the_DT immunodominant_JJ epitopes_NNS ,_, gD1-29_JJ ,_, gD49-82_JJ ,_, gD146-179_JJ ,_, gD287-317_JJ ,_, and_CC gD332-358_JJ and_CC also_RB to_TO gD22-52_NN ,_, gD77-104_NN ,_, gD96-123_NN ,_, and_CC gD121-152_NN ,_, which_WDT represent_VBP subdominant_JJ epitopes_NNS ._SENT Immunization_NN with_IN a_DT pool_NN of_IN the_DT newly_RB identified_VBN CD4+_NP Th1_NP immunodominant_JJ gD_NN peptide_NN epitopes_NNS resulted_VBN in_IN prolonged_JJ survival_NN upon_IN a_DT lethal_JJ HSV-1_JJ challenge_NN ._SENT |_SYM To_TO investigate_VB whether_IN the_DT Th1-_NP or_CC Th2-type_NP immune_JJ responses_NNS are_VBP more_RBR important_JJ for_IN protection_NN from_IN HSV-1_JJ infection_NN ,_, mice_NNS were_VBD immunized_VBN with_IN either_DT CD4+_NP Th1_NP peptide_NN epitopes_NNS (_( gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN )_) or_CC CD4+_NP Th2_NP peptide_NN epitopes_NNS (_( gD22-52_NP ,_, gD77-104_NP ,_, gD200-234_NN ,_, and_CC gD287-317_JJ )_) ._SENT The_DT previously_RB described_VBN protective_JJ epitope_NN gD1-29_NN was_VBD excluded_VBN from_IN these_DT experiments_NNS ._SENT Groups_NNS of_IN 10_CD H-2d_JJ mice_NNS were_VBD immunized_VBN twice_RB with_IN the_DT following_NN :_: a_DT pool_NN of_IN gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN emulsified_VBN in_IN M-ISA-720_NP adjuvant_NN or_CC a_DT pool_NN of_IN gD22-52_JJ ,_, gD77-104_JJ ,_, gD121-152_JJ ,_, and_CC gD200-234_NN emulsified_VBN in_IN M-ISA-720_NP adjuvant_JJ or_CC M-ISA-720_JJ alone_RB (_( adjuvant-injected_JJ control_NN )_) ,_, or_CC they_PP were_VBD left_VBN untreated_JJ (_( nonimmunized_JJ control_NN )_) ._SENT Twenty_CD days_NNS after_IN the_DT second_JJ dose_NN of_IN peptide_NN vaccine_NN ,_, mice_NNS were_VBD challenged_VBN with_IN 2_CD x_SYM 105_CD PFU_NP of_IN the_DT McKrae_NP strain_NN of_IN HSV-1_NP per_IN eye_NN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Mice_NNS were_VBD monitored_VBN for_IN 4_CD weeks_NNS after_IN ocular_JJ HSV-1_JJ challenge_NN for_IN their_PP$ ability_NN to_TO withstand_VB a_DT lethal_JJ infection_NN with_IN HSV-1_NP ._SENT All_DT of_IN the_DT mice_NNS that_WDT died_VBD following_VBG challenge_NN did_VBD so_RB between_IN days_NNS 8_CD and_CC 12_CD postinfection_NN ._SENT All_DT of_IN the_DT H-2d_JJ mice_NNS immunized_VBN with_IN the_DT pool_NN of_IN Th1_JJ peptide_NN epitopes_NNS survived_VBD the_DT lethal_JJ HSV-1_JJ challenge_NN ._SENT In_IN contrast_NN ,_, less_JJR than_IN 50_CD %_NN of_IN the_DT H-2d_JJ mice_NNS immunized_VBN with_IN the_DT pool_NN of_IN Th2_JJ peptide_NN epitopes_NNS survived_VBD ._SENT Only_RB 10_CD %_NN of_IN adjuvant-injected_JJ and_CC 10_CD %_NN of_IN nonimmunized_JJ control_NN H-2d_NN mice_NNS survived_VBD the_DT HSV-1_JJ challenge_NN ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT Th1_JJ peptide_NN epitopes_NNS provided_VBD more_JJR protection_NN against_IN lethal_JJ ocular_JJ HSV-1_JJ challenge_NN than_IN did_VBD the_DT Th2_JJ peptide_NN epitopes_NNS (_( P_NN =_SYM 0.0003_CD )_) ._SENT Depletion_NN of_IN CD4+_NP T_NN cells_NNS abolishes_VBZ the_DT protective_JJ response_NN ._SENT |_SYM To_TO determine_VB the_DT involvement_NN of_IN CD4+_NP and_CC CD8+_NP T_NN cells_NNS in_IN induced_VBN protection_NN ,_, mice_NNS were_VBD immunized_VBN with_IN gD49-82_JJ ,_, gD146-179_JJ ,_, gD228-257_JJ ,_, and_CC gD332-358_NN peptides_NNS and_CC were_VBD then_RB divided_VBN into_IN 4_CD groups_NNS of_IN 10_CD ._SENT The_DT groups_NNS were_VBD then_RB either_RB depleted_VBN of_IN CD4+_NP T_NN cells_NNS ,_, depleted_VBN of_IN CD8+_NP T_NN cells_NNS ,_, left_VBD untreated_JJ (_( none_NN )_) ,_, or_CC treated_VBN with_IN irrelevant_JJ antibodies_NNS (_( rat_NN immunoglobulin_NN G_NP [_SYM IgG_NP ]_SYM or_CC IgG_NP control_NN )_) ._SENT All_DT four_CD groups_NNS were_VBD then_RB challenged_VBN with_IN HSV-1_NP as_RB described_VBD above_IN ._SENT Depletion_NN of_IN CD4+_NP T_NN cells_NNS resulted_VBN in_IN the_DT death_NN of_IN all_DT infected_JJ mice_NNS (_( Table_NP ;_: P_NN =_SYM 0.0001_CD )_) ._SENT However_RB ,_, depletion_NN of_IN CD8+_NP T_NN cells_NNS or_CC injection_NN of_IN control_NN rat_NN IgG_NP antibodies_NNS did_VBD not_RB significantly_RB impair_VB the_DT induced_VBN protective_JJ immunity_NN (_( P_NN =_SYM 0.47_CD or_CC 1_CD ,_, respectively_RB )_) ._SENT These_DT results_NNS demonstrated_VBD that_IN ,_, in_IN this_DT system_NN ,_, CD4+_NP T_NN cells_NNS are_VBP required_VBN and_CC CD8+_JJ T_NN cells_NNS are_VBP not_RB sufficient_JJ for_IN protective_JJ immunity_NN against_IN lethal_JJ ocular_JJ HSV-1_JJ challenge_NN ._SENT HSV_NP infection_NN is_VBZ a_DT major_JJ cause_NN of_IN a_DT spectrum_NN of_IN morbidity_NN and_CC clinical_JJ diseases_NNS in_IN humans_NNS ._SENT During_IN the_DT last_JJ decade_NN ,_, HSV_NP vaccine_NN development_NN has_VBZ primarily_RB focused_VBN on_IN various_JJ forms_NNS of_IN recombinantly_RB expressed_VBN glycoproteins_NNS ._SENT Of_IN the_DT 11_CD known_JJ HSV_NP glycoproteins_NNS ,_, gD_NN is_VBZ the_DT most_RBS highly_RB conserved_VBN and_CC the_DT most_RBS antigenically_RB cross-reactive_JJ between_IN HSV-1_NP and_CC HSV-2_NP ._SENT gD_NN has_VBZ emerged_VBN as_IN an_DT excellent_JJ candidate_NN Ag_NP for_IN inducing_VBG a_DT protective_JJ immunity_NN in_IN animal_JJ models_NNS against_IN ocular_JJ and_CC genital_JJ infections_NNS with_IN both_DT types_NNS of_IN HSV_NP ._SENT It_PP has_VBZ recently_RB been_VBN reported_VBN in_IN a_DT large_JJ human_JJ genital_JJ HSV_NP trial_NN that_IN immunization_NN with_IN recombinant_JJ gD_NNS induced_VBD significant_JJ protection_NN in_IN women_NNS who_WP were_VBD seronegative_JJ for_IN HSV_NP but_CC was_VBD ineffective_JJ in_IN seropositive_JJ women_NNS and_CC in_IN men_NNS ._SENT The_DT antibody_NN response_NN to_TO this_DT vaccine_NN was_VBD similar_JJ to_TO natural_JJ HSV_NP infection_NN ,_, but_CC demonstration_NN of_IN its_PP$ ability_NN to_TO induce_VB T-cell_NN responses_NNS was_VBD restricted_VBN by_IN the_DT limited_JJ knowledge_NN of_IN gD_JJ T-cell_NN epitopes_NNS (_( ,_, ,_, -_: )_) ._SENT Identification_NN and_CC molecular_JJ characterization_NN of_IN the_DT CD4+_NP T-cell_NN epitope_NN repertoire_NN of_IN gD_NNS would_MD contribute_VB to_TO a_DT better_JJR understanding_NN of_IN the_DT immune_JJ correlates_NNS of_IN protection_NN and_CC would_MD help_VB in_IN developing_VBG effective_JJ immunotherapeutic_JJ and_CC immunoprophylactic_JJ strategies_NNS ._SENT There_EX are_VBP three_CD principal_JJ findings_NNS in_IN the_DT present_JJ report_NN ._SENT First_RB ,_, the_DT combined_JJ approach_NN of_IN epitope_NN prediction_NN performed_VBN by_IN using_VBG the_DT TEPITOPE_NP algorithm_NN and_CC the_DT rapid_JJ determination_NN of_IN immunogenicity_NN in_IN mice_NNS ,_, with_IN a_DT wide_JJ range_NN of_IN MHC_NP restriction_NN ,_, proved_VBD to_TO be_VB a_DT useful_JJ strategy_NN for_IN identifying_VBG T-cell_NN epitope-bearing_VBG regions_NNS from_IN the_DT sequence_NN of_IN a_DT key_JJ immunogenic_JJ HSV_NP protein_NN ._SENT Second_JJ ,_, appropriate_JJ medium-sized_JJ peptides_NNS carefully_RB selected_VBN from_IN the_DT putative_JJ gD_NN sequence_NN and_CC emulsified_VBN in_IN a_DT human-compatible_JJ adjuvant_NN M-ISA-720_NP mainly_RB induced_VBD potent_JJ IFN-gamma-_NP and_CC IL-2-secreting_NP CD4+_NP T_NN cells_NNS that_WDT recognized_VBD naturally_RB processed_VBN epitopes_NNS ._SENT Third_JJ ,_, and_CC of_IN particular_JJ interest_NN ,_, immunization_NN with_IN a_DT pool_NN of_IN newly_RB identified_VBN CD4+_NP Th1_NP gD_NN peptide_NN epitopes_NNS elicited_VBD a_DT CD4-dependent_JJ protective_JJ immunity_NN against_IN a_DT lethal_JJ ocular_JJ HSV-1_JJ challenge_NN ._SENT Among_IN the_DT advantages_NNS of_IN an_DT epitope-based_JJ vaccine_NN approach_NN over_IN the_DT conventional_JJ whole-protein_NN approach_NN is_VBZ the_DT possibility_NN of_IN including_VBG multiple_JJ immunodominant_NN and_CC subdominant_JJ epitopes_NNS ._SENT This_DT strategy_NN may_MD offer_VB an_DT opportunity_NN to_TO elicit_VB responses_NNS superior_JJ to_TO that_DT induced_VBN following_VBG HSV_NP infection_NN or_CC even_RB following_VBG immunization_NN by_IN recombinantly_RB expressed_VBN glycoproteins_NNS ._SENT Several_JJ gD_JJ peptide_NN epitopes_NNS selected_VBN in_IN the_DT present_JJ study_NN induced_VBD potent_JJ HSV-specific_NP CD4+_NP Th1-like_JJ T-cell_NN responses_NNS ,_, with_IN production_NN of_IN high_JJ levels_NNS of_IN IFN-gamma_NP and_CC IL-2_NP ,_, cytokines_NNS that_WDT play_VBP a_DT significant_JJ role_NN in_IN host_NN response_NN to_TO HSV_NP ._SENT In_IN addition_NN ,_, we_PP demonstrated_VBD an_DT enhancement_NN in_IN the_DT immunogenicity_NN of_IN gD_NN peptides_NNS injected_VBN as_IN a_DT pool_NN ,_, supporting_VBG the_DT concept_NN that_IN combining_VBG potent_JJ immunogenic_JJ epitopes_NNS may_MD be_VB a_DT practical_JJ way_NN to_TO create_VB a_DT broader_JJR and_CC a_DT more_RBR potent_JJ T-cell_NN response_NN ._SENT Numerous_JJ potential_JJ T-cell_NN epitopes_NNS could_MD theoretically_RB be_VB generated_VBN from_IN a_DT protein_NN Ag_NP ._SENT However_RB ,_, in_IN practice_NN ,_, T_NN cells_NNS tend_VBP to_TO focus_VB upon_IN just_RB a_DT few_JJ immunodominant_NN epitopes_NNS ,_, whereas_IN discrete_JJ cryptic_JJ epitopes_NNS remain_VBP hidden_VBN to_TO the_DT immune_JJ system_NN ._SENT Identification_NN of_IN such_JJ immunogenic_JJ epitopes_NNS from_IN among_IN the_DT often_JJ hundreds_NNS or_CC thousands_NNS of_IN amino_NN acids_NNS comprising_VBG HSV_NP proteins_NNS could_MD be_VB a_DT cumbersome_JJ and_CC laborious_JJ process_NN ._SENT Traditional_JJ approaches_NNS for_IN identifying_VBG such_JJ epitopes_NNS from_IN among_IN the_DT often_JJ hundreds_NNS or_CC thousands_NNS of_IN amino_NN acids_NNS that_WDT cover_VBP the_DT entire_JJ sequence_NN of_IN a_DT protein_NN Ag_NP have_VBP generally_RB involved_VBN synthesizing_VBG scores_NNS of_IN overlapping_JJ peptides_NNS (_( "_`` overlapping-peptide_NN method_NN "_'' )_) and_CC extensive_JJ screening_NN of_IN T-cell_NN clones_NNS isolated_VBN from_IN whole_JJ Ag-stimulated_JJ cells_NNS ._SENT The_DT overlapping-peptide_NN method_NN might_MD not_RB automatically_RB map_VB the_DT same_JJ epitope_NN peptides_NNS predicted_VBD in_IN our_PP$ study_NN from_IN using_VBG the_DT TEPITOPE_NP algorithm_NN ._SENT Indeed_RB ,_, using_VBG the_DT overlapping-peptide_NN method_NN ,_, one_PP can_MD imagine_VB that_IN the_DT regions_NNS where_WRB these_DT peptides_NNS overlap_VBP might_NN by_IN themselves_PP contain_VBP "_`` junctional_JJ epitopes_NNS "_'' ._SENT Shortening_VBG or_CC lengthening_VBG a_DT peptide_NN by_IN one_CD or_CC a_DT few_JJ amino_NN acids_NNS might_MD sometime_RB result_VB in_IN missing_VBG junctional_JJ epitopes_NNS that_WDT might_MD be_VB present_JJ in_IN the_DT overlapping_JJ regions_NNS ._SENT In_IN addition_NN ,_, a_DT major_JJ drawback_NN of_IN the_DT overlapping-peptide_NN method_NN is_VBZ the_DT number_NN of_IN peptide_NN sequences_NNS that_WDT need_VBP to_TO be_VB synthesized_VBN and_CC tested_VBN ,_, thus_RB making_VBG it_PP an_DT expensive_JJ ,_, labor-intensive_JJ ,_, and_CC time-consuming_JJ process_NN ._SENT In_IN addition_NN ,_, progress_NN on_IN the_DT mapping_NN of_IN T-cell_NN epitopes_NNS has_VBZ been_VBN slow_RB due_JJ to_TO reliance_NN on_IN studies_NNS of_IN clones_NNS ,_, an_DT approach_NN that_WDT generally_RB involves_VBZ extensive_JJ screening_NN of_IN T-cell_NN precursors_NNS isolated_VBN from_IN whole_JJ Ag-stimulated_JJ cells_NNS ._SENT Candidate_NN T-cell_NN peptide_NN epitopes_NNS can_MD be_VB also_RB screened_VBN based_VBN on_IN their_PP$ affinity_NN to_TO interact_VB in_IN vitro_NN with_IN HLA_NP class_NN II_NP molecules_NNS ._SENT However_RB ,_, the_DT high_JJ polymorphism_NN of_IN HLA_NP class_NN II_NP molecules_NNS is_VBZ a_DT major_JJ drawback_NN in_IN the_DT identification_NN of_IN CD4+_NP T-cell_NN epitopes_NNS with_IN large_JJ population_NN coverage_NN ._SENT Another_DT alternative_NN to_TO cloning_VBG T_NN cells_NNS has_VBZ employed_VBN the_DT elegant_JJ technology_NN of_IN tetramer-guided_JJ epitope_NN mapping_NN ,_, which_WDT offers_VBZ the_DT opportunity_NN for_IN a_DT straightforward_JJ cloning_VBG of_IN the_DT Ag-specific_JJ T_NN cells_NNS through_IN single-cell_NN sorting_VBG ._SENT However_RB ,_, besides_IN needing_VBG to_TO form_VB pools_NNS of_IN overlapping_JJ peptides_NNS with_IN this_DT technology_NN ,_, there_EX are_VBP concerns_NNS that_IN relevant_JJ peptides_NNS present_JJ in_IN the_DT pool_NN will_MD be_VB competed_VBN out_RP by_IN irrelevant_JJ peptides_NNS ._SENT In_IN addition_NN ,_, the_DT relative_JJ instability_NN of_IN MHC_NP class_NN II_CD tetramers_NNS (_( compared_VBN to_TO MHC_NP class_NN I_CD tetramers_NNS )_) points_VBZ out_RP that_IN the_DT tetramer_NN approach_NN still_RB needs_VBZ improvement_NN ._SENT Relatively_RB laborious_JJ strategies_NNS identified_VBN small_JJ subsets_NNS of_IN candidate_NN epitopes_NNS by_IN sequencing_VBG peptides_NNS eluted_VBN from_IN purified_VBN MHC_NP molecules_NNS from_IN pathogen-infected_JJ cells_NNS and_CC then_RB testing_VBG their_PP$ MHC_NP binding_JJ affinity_NN ._SENT High-affinity_NN peptides_NNS are_VBP then_RB tested_VBN for_IN their_PP$ ability_NN to_TO induce_VB pathogen-specific_JJ T_NN cells_NNS ._SENT Murine_JJ class_NN II-restricted_JJ Th_NN lymphocyte_NN epitopes_NNS have_VBP been_VBN described_VBN as_IN cross-reacting_NN with_IN HLA-DR_NP molecul_NP 